Research ArticleBIOMARKERS

Distinct plasma immune signatures in ME/CFS are present early in the course of illness

See allHide authors and affiliations

Science Advances  27 Feb 2015:
Vol. 1, no. 1, e1400121
DOI: 10.1126/sciadv.1400121

eLetters is an online forum for ongoing peer review. Submission of eLetters are open to all . Please read our guidelines before submitting your own eLetter.

Compose eLetter

Plain text

  • Plain text
    No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Author Information
First or given name, e.g. 'Peter'.
Your last, or family, name, e.g. 'MacMoody'.
Your email address, e.g.
Your role and/or occupation, e.g. 'Orthopedic Surgeon'.
Your organization or institution (if applicable), e.g. 'Royal Free Hospital'.
Statement of Competing Interests

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Vertical Tabs

  • Why a 3-year cutoff?
    • Mats Reimer, Pediatrician, Child Clinic Molnlycke SWEDEN

    Would the difference between early cases, late cases and controls still be statistically significant if another arbitrary cutoff (e.g. 2, 4 or 5 years) was choosen?

    Competing Interests: None declared.
  • RE: a need for validated data to avoid false hope for patients suffering chronic fatigue syndrome
    • Laurent Chiche, Internal Medecine, Hopital Europeen, Marseille, France
    • Other Contributors:
      • Frederique Retornaz, Internal Medecine, Hopital Europeen, Marseille, France

    We read with interest the article by Hornig et al published in the Journal. Although authors should be commended for conducting such important study on patients suffering chronic fatigue syndrome (CFS), we suggest that the conclusions of their paper (“the presence of a specific immune profile early in the course of CFS has important implications for the diagnostic process”) may be strongly tempered.
    Indeed, in our opinion, numerous methodological issues prevent from translating reported results into routine practice to improve the diagnosis of CFS. First, we do not agree with the choice not to use adjustment for multiple comparisons although CFS patients (or cases) were compared to healthy controls for no less than 51 parameters. Indeed, observed differences yielded only p value close to the statistical significance cutoff, and one can wonder if applying multiple comparisons adjustment such as the Benjamini and Hochberg method (used by authors elsewhere in the manuscript) would not have led to the absence of any significant differences. Second, the differences observed between cases (CFS) and controls were so “biologically” small (ie, IL-6 mean levels were 10.2 pg/ml in cases versus 10.9 pg/ml in controls) that authors focused on the differences observed instead with 2 subsets of cases: short versus long duration CFS. Of importance, these differences could have been at least partially related to major differences in the characteristics of patients (short duration CFS...

    Show More
    Competing Interests: None declared.

Stay Connected to Science Advances

Navigate This Article